| Thank you to our sponsors. |
|
|
Founded in 2004, BioStrategy Partners is a virtual incubator providing technology and business development services to emerging-stage life sciences companies and university-based research projects in the Greater Philadelphia region. BioSP specializes in offering business guidance and support to first-time entrepreneurs, scientific founders, and university-based principal investigators. For more information, please visit our web site, http://www.biostrategypartners.org.
| |
|
From the Executive Director
Karen J. Hanson, Ph.D. |
|
In this month's edition of BioNewslink, we feature an article by Maureen O'Leary, Ph.D. about BioSP's new Commercialization Germinator for university-based research projects. Maureen, who is our Program Director, has over ten years' experience in the many aspects of moving technologies from the laboratory to commercial environments, including Director of Start-Up Business Development at the University of Pennsylvania's Center for Technology Transfer, where she helped launch 15 startup companies. We are excited about our Germinator, as you'll see below! Please visit our web site at www.biostrategypartners.org for more information. |
| Practical Knowledge Series:
Upcoming Programs |
|
|
The FDA Quagmire:Requirements and Strategies for
Approvals
Thursday, March 12, 2009
3:30PM - 5:30PM
Lankenau Institute for Medical Research
The Walter and Lenore Annenberg Conference Center
Classroom 101B
190 Lancaster Avenue
Wynnewood, PA 19096
|
|
The Unasked Question
By Maureen O'Leary, Program Director |
|
|
Why do you work with BioSP?
BioSP is one of the few organizations that will work with first time entrepreneurs and pre-seed companies. This is truly unique. But what I get excited about is the new Germinator program.
The Germinator program allows us to help develop technology that is too early to leave the lab. In the past, entrepreneurs and investigators were forced to burn a lot of time and energy trying to create a company around a project that is simply not ready for seed investment. The Germinator program creates a structure through which an outside advisory team provides the feedback and expertise of a strategic/scientific advisory board - without the overhead of starting the company, executing a license, etc. These projects stay in the research institution, hopefully funded by federal funding, and receive the benefit of commercial guidance specifically tailored to their project.
At the end of the project the technology transfer office has focused research results and market feedback. They are in a much stronger position with respect to licensing options.
|
| News From Our Community |
|
BioLeap LLC, a global leader in predictive drug discovery, announced the appointment of David L. Pompliano, Ph.D. as CEO at BioLeap.
"David has been working very closely with me and the BioLeap team as an Advisor to the company, and is uniquely qualified to take on this important leadership role.", commented John Kulp, PhD, Chairman and Chief Technical Officer of BioLeap. "His executive experience managing drug discovery teams will enable him to drive BioLeap to realize its corporate mission of developing numerous high-quality clinical candidates for anti-infectives and other, often intractable, therapeutic targets. Read MoreRichman Chemical Inc. (RCI) has tapped its capable network of partners to now offer high potency chemical manufacturing in a cGMP environment to its customers. A high potency active pharmaceutical ingredient (HPAPI) is a drug that carries a higher strength with a smaller amount of actual active pharmaceutical ingredient. Maintaining safety and efficacy while responding to the time sensitive nature inherent to life science firms needing to manufacture these HPAPIs has placed RCI in a pivotal position to respond to this growing requirement.
Prescient Medical is pleased to announce that the first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect™ Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. The 64-year-old man is enrolled in SECRITT I, a pilot study designed to evaluate the vProtect™ Luminal Shield as a treatment for vulnerable plaques-"silent" atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences. Read More | |
|
